GlassScriptPhysician profile
Prathyusha Pamidi Larson
NPI 1700414596
$3,596.59
in general payments reported to CMS, 2019-2025
23 companies · $1,522 in 2025
The $1,522 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $470 · 2024: $1,604 · 2025: $1,522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,596.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $540.64 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $330.30 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $308.69 | 2023-2025 | |
| Amgen INC. | $301.49 | 2023-2025 | Evenity, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $285.94 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $277.90 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $243.60 | 2023-2025 | |
| Lilly USA, LLC | $209.91 | 2023-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $187.99 | 2023-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $146.10 | 2023-2025 | Xifaxan, Trulance |
| Intuitive Surgical, INC. | $125.53 | 2025 | |
| Phathom Pharmaceuticals, INC. | $102.11 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $97.37 | 2023-2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Dexcom, INC. | $97.03 | 2023-2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $76.53 | 2025 | Caplyta |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $75.61 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ibsa Pharma INC. | $53.66 | 2024-2025 | Licart, Tirosint, Flector |
| Vanda Pharmaceuticals INC. | $28.23 | 2025 | Fanapt |
| Kowa Pharmaceuticals America, INC. | $27.98 | 2025 | Zoryve |
| Idorsia Pharmaceuticals US INC | $23.54 | 2024 | Quviviq |
| Lundbeck LLC | $23.31 | 2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $17.16 | 2023 | Xarelto |
| Esperion Therapeutics, INC. | $15.97 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prathyusha Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.